Type 2 Diabetes Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are female.
- People aged between 48 and 58 years old.
- People who are in the menopausal transition phase, meaning either pre-menopause or peri-menopause (the period leading up to menopause).
- People who have been diagnosed with Type 2 Diabetes.
- People who have and regularly use a smartphone with internet access.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are male.
- People who are currently pregnant.
- People who have previously had a full hysterectomy (surgical removal of the uterus) or had both ovaries removed.
- People who have previously been diagnosed with a heart or blood vessel condition, including coronary heart disease, heart failure, congenital heart disease, stroke, mini-stroke (transient ischemic attack), heart valve disease, peripheral vascular disease, aorta problems, atrial fibrillation or flutter, or any other cardiovascular disease.
- People who have a serious mental health condition that is currently untreated (for example, untreated psychosis).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kerri Anne Mullen, Ph.D., Ottawa Heart Institute Research Corporation
Phone: 613-696-7000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Reduced septal e' velocity; Increased E/e' ratio; Increased tricuspid regurgitation (TR) velocity; Change in pulmonary artery systolic pressure (PASP); Change in E/A ratio; Change in left atrial size
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.